Regulatory Affairs Partnership: AI-Powered Guid

---

Successfully navigating the intricate and evolving global regulatory landscape for advanced and rare disease therapies requires specialized strategic foresight and deep technical expertise. As a committed non-profit partner, Regal Intel offers comprehensive regulatory affairs support, leveraging AI-powered intelligence to strea

We collaborate with you to develop tailored regulatory strategies that align directly with your mission objectives and the specific needs of your rare disease program, aiming to expedite patient access. Our expertise encompasses the entire product lifecycle, addressing unique considerations for rare disease therapies, including managing post-approval commitments.

• Global Regulatory Intelligence: We provide focused, up-to-date regulatory intelligence using AI to monitor new guidance documents, agency initiatives, and policy changes. Our AI-driven dashboards can deliver real-time warnings regarding the latest global, federal, and state legislation.
• Dossier Preparation: AI tools can accelerate the preparation of regulatory submissions, reduce human error, and proactively address anticipated queries to shorten review cycles. We can use AI to identify trends and detect irregularities in documents that might be holding up product approval.
• Navigating Expedited Pathways: We specialize in helping partners strategically identify, pursue, and maintain designations under expedited pathways for qualifying groundbreaking therapies. Our guidance includes FDA programs like Breakthrough Therapy Designation (BTD), Regenerative Medicine Advanced 

AI's potential to accelerate drug development by leveraging data sets for better trial outcomes and faster therapy delivery is clear. By using AI to support our regulatory work, we can expedite the development of more precise treatments at a lower cost than traditional drug discovery.

Our AI-powered platform can:

• Predict Outcomes: Use AI to predict clinical trial outcomes, and provide real-time insights into the safety and efficacy of care.
• Identify Candidates: AI models can identify drug candidates for over 17,000 rare diseases, many of which have no current treatments.
• Promote Collaboration: We utilize AI techniques like federated learning to enable analysis without direct data access, promoting data sharing while minimizing reidentification risks and complying with data privacy regulations.

We are not just a service provider; we are a dedicated, mission-aligned partner offering cost-effective, high-impact regulatory support tailored to the needs of the rare disease community. Our unique combination of specialized global expertise and AI-driven capabilities ensures that your therapy's path to market is efficient and effective.